Interventional News’ top 10 most popular stories of January 2023


TOP 10

Interventional News’ most popular stories in the opening month of 2023 included news of first enrolments in clinical studies of peripheral arterial disease (PAD) and deep vein thrombosis (DVT), respectively; key takeaways from a conference myth-busting session centring on being a woman in interventional radiology (IR); and an update on patients treated with tumour-specific electroporation (TSE) in Ukraine.

1) Penumbra launches Lightning Flash mechanical thrombectomy system

Penumbra announced the US Food and Drug Administration (FDA) clearance and launch of its Lightning Flash mechanical thrombectomy system.

2) Cardiovascular Systems enrols first patient in Japan for KAIZEN clinical study

Cardiovascular Systems Inc (CSI) recently announced initiation of the KAIZEN clinical study of its Diamondback 360 peripheral orbital atherectomy system (OAS) for the treatment of calcified plaque in patients with PAD.

3) Cardiovascular Systems announces 510(k) submission of Innova Vascular’s thrombectomy system

Cardiovascular Systems (CSI) announced that Innova Vascular (Innova) has submitted a 510(k) premarket notification to the US Food and Drug Administration (FDA) for its thrombectomy devices intended to treat peripheral vascular disease.

4) BSIR busts myths around being a girl in the IR “gang”

Paula Novelli (University of Pittsburgh Medical Center, Pittsburgh, USA) put her own spin on a British Society of Interventional Radiology (BSIR) annual scientific meeting (2–4 November, Glasgow, UK) presentation titled ‘Women are more likely to work part-time’. She brought the perspective of ‘the only girl in the gang’—the gang being her IR team at Pittsburgh.

5) Inari Medical announces first enrolment in DEFIANCE trial evaluating clinical outcomes of ClotTriever system in DVT

Inari Medical has announced that the first patient has been enrolled in DEFIANCE, a prospective randomised controlled trial (RCT) comparing the clinical outcomes of patients with iliofemoral DVT treated with the ClotTriever system versus anticoagulation only.

6) Funding secured to advance development of Pulse IVL system

AVS has announced that it raised US$20 million in Series B financing, which the company says will accelerate clinical trial timelines for its device for peripheral application in pulsatile intravascular lithotripsy (PIVL) cases and advance development and preclinical work on a PIVL device for coronary cases.

7) Rivermark Medical announces successful use of its FloStent System

Rivermark Medical has announced the successful first-in-human (FIH) use of its FloStent System as part of the company’s RAPID-1 FIH clinical study, which is evaluating the delivery, safety, and clinical effectiveness of the FloStent System for treating the symptoms of benign prostatic hyperplasia (BPH).

8) ESVS AAA guidelines alert recommends “enhanced surveillance” in patients treated with Nellix device

In a newly released “focused update” to its 2019 recommendations, the European Society for Vascular Surgery (ESVS) abdominal aortic aneurysm (AAA) guidelines writing committee has published advice on the surveillance and management of patients treated with the Nellix endovascular aneurysm sealing (EVAS) system (Endologix).

9) GE Healthcare announces agreement to acquire Imactis

GE Healthcare announced it has entered into an agreement to acquire Imactis, an innovator in computed tomography (CT) interventional guidance across an array of care areas.

10) Pancreatic cancer patients in Ukraine treated with TSE

A team of specialists at Ulis Hospital (Ulis, Ukraine) has recently reported that the quality-of-life of the two pancreatic cancer patients treated with TSE in September 2022 continues to improve.


Please enter your comment!
Please enter your name here